U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4209177
- 153 Pages
- January 2021
- Medical Devices
Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.
The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.
Rise in geriatric population is the major factor that drives growth of the U.S. pain management drugs market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth. The U.S. pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.
On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. On the basis of pain type, the market is segmented into chronic and acute pain.
The key players operating in the U.S. pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Boehringer Ingelheim, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current U.S. pain management drugs market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2020 to 2027.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
• By Drug Class
o NSAIDS
o Anesthetics
o Anticonvulsants
o Antimigraine Agents
o Antidepressants
o Opioids
o Nonnarcotic Analgesics
• By Indication
o Arthritic Pain
o Neuropathic Pain
o Cancer Pain
o Chronic Back Pain
o Postoperative Pain
o Migraine
o Fibromyalgia
o Bone fracture
o Muscle sprain/strain
o Acute appendicitis
o Others
• By Pain type
o Chronic pain
o Acute pain
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in incidences of chronic diseases
3.5.1.2.Favorable regulatory scenario
3.5.1.3.Increase in geriatric population
3.5.2.Restraints
3.5.2.1.Availability of alternative therapies
3.5.2.2.Drug exploitation
3.5.2.3.Patent expiration of prescription drugs
3.5.3.Opportunity
3.5.3.1.Advancements in drug development
3.5.4.Impact Analysis
3.6.COVID-19 impact analysis for U.S. Pain Management Drugs
CHAPTER 4:U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NSAIDS
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.4.Anticonvulsants
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.5.Antimigraine drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.6.Antidepressants
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast
CHAPTER 5:U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic pain
5.2.1.Market size and forecast
5.3.Neuropathic pain
5.3.1.Market size and forecast
5.4.Cancer pain
5.4.1.Market size and forecast
5.5.Chronic back pain
5.5.1.Market size and forecast
5.6.Post-operative pain
5.6.1.Market size and forecast
5.7.Migraine
5.7.1.Market size and forecast
5.8.Fibromyalgia
5.8.1.Market size and forecast
5.9.Bone fracture
5.9.1.Market size and forecast
5.10.Muscle sprain/strain
5.10.1.Market size and forecast
5.11.Acute appendicitis
5.11.1.Market size and forecast
5.12.Others
5.12.1.Market size and forecast
CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Chronic pain
6.2.1.Market size and forecast
6.3.Acute pain
6.3.1.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.ELI LILY AND COMPANY
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.GLAXOSMITHKLINE PLC (GSK)
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments
7.5.JOHNSON & JOHNSON
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.MERCK & CO., INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MYLAN N.V.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.NOVARTIS INTERNATIONAL AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.PFIZER INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.PURDUE PHARMA L.P.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments
TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 04.ABBOTT: COMPANY SNAPSHOT
TABLE 05.ABBOTT: OERATING SEGMENT
TABLE 06.ABBOTT: PRODUCT PORTFOLIO
TABLE 07.BOEHRINGER INGELHEIM : COMPANY SNAPSHOT
TABLE 08.BOEHRINGER INGELHEIM : OPERATING SEGMENTS
TABLE 09.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 10.ELI LILLY: COMPANY SNAPSHOT
TABLE 11.LILLY: OPERATING SEGMENTS
TABLE 12.ELI LILLY: PRODUCT PORTFOLIO
TABLE 13.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14.GSK: COMPANY SNAPSHOT
TABLE 15.GSK: OPERATING SEGMENTS
TABLE 16.GSK: PRODUCT PORTFOLIO
TABLE 17.J&J: COMPANY SNAPSHOT
TABLE 18.J&J: OPERATING BUSINESS SEGMENTS
TABLE 19.J&J: PRODUCT PORTFOLIO
TABLE 20.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 21.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 22.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 23.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24.MYLAN: COMPANY SNAPSHOT
TABLE 25.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 26.MYLAN: PRODUCT PORTFOLIO
TABLE 27.NOVARTIS: COMPANY SNAPSHOT
TABLE 28.NOVARTIS: OPERATING SEGMENTS
TABLE 29.NOVARTIS: PRODUCT PORTFOLIO
TABLE 30.PFIZER: COMPANY SNAPSHOT
TABLE 31.PFIZER: OERATING SEGMENT
TABLE 32.PFIZER: PRODUCT PORTFOLIO
TABLE 33.PURDUE: COMPANY SNAPSHOT
TABLE 34.PURDUE: PRODUCT PORTFOLIO
Similar Reports
This report provides an overview of the French molecular diagnostic testing market, including test volume, and sales forecasts by Application, 2019-2023, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
This report provides an overview of the German molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
This report provides an overview of the Italian molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
